discomfort; swelling on top bridge of my nose on both side; swelling of face; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority. the reporter is the patient. other case identifier(s): gb-mhra-vac-202202121517348540-sxlgy (regulatory authority), gb-mhra-adr 26597874 (regulatory authority). a 38 year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 11feb2022 (batch/lot number: unknown) at the age of 38 years as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: covid-19 vaccine (dose 1; manufacturer unknown), for covid-19 immunisation; bnt162b2 (dose 2, lot-unknown), for covid-19 immunisation, reaction(s): "swelling at the top bridge of my nose on one side". the following information was reported: swelling face (medically significant) with onset 11feb2022, outcome "not recovered", described as "swelling of face"; discomfort (medically significant), outcome "unknown", described as "discomfort"; swelling (medically significant), outcome "unknown", described as "swelling on top bridge of my nose on both side". therapeutic measures were not taken as a result of swelling face, discomfort, swelling. patient was not on medication, never had facial fillers. patient is not pregnant, patient is not currently breastfeeding. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected.; sender's comments: linked report(s) : gb-pfizer inc-202200307909 same patient/drug and different dose/events